CD274 and neoplasm: Taken together, CD4+, FOXP3+, PD-L1 TILs and PD-L1 tumor cells possess the potential to predict the recurrence risk of DCIS, and the stromal PD-L1 is more valuable than the others in evaluating DCIS recurrence risk.